P-094 - KEYNOTE-811 pembrolizumab plus trastuzumab and chemotherapy for HER2+ metastatic gastric or gastroesophageal junction cancer: a double-blind, randomized, placebo-controlled phase 3 study.

Authors :: Chung, H.
Bang, Y.
Fuchs, C.
Qin, S.
Satoh, T.
Shitara, K.
Tabernero, J.
Van Cutsem, E.
Cao, Z.
Chen, X.
Kang, S.
Shih, C.
Janjigian, Y.
Source :: Annals of Oncology. 2019 Supplement, Vol. 30, piv25-iv25. 1p.
Publication Year :: 2019

Subjects :: *ESOPHAGOGASTRIC junction
*TRASTUZUMAB
*PEMBROLIZUMAB
*CANCER chemotherapy
*METASTASIS
*GASTRIC bypass

Full Text Access

Tools